Table 7.
HRs and corresponding 95% CIs of SOX2-OT overexpression in tumors based on The Cancer Genome Atlas (TCGA) datasets.
| OS | ||
|---|---|---|
| HR (95% CI) | P Value | |
| TCGA-LAML | 1.062(0.681–1.656) | 0.789 |
| TCGA-ACC | 0.407(0.192–0.862) | 0.017 |
| TCGA-BLCA | 1.317(0.98–1.769) | 0.064 |
| TCGA-BRCA | 1.481(1.033–2.123) | 0.02 |
| TCGA-CESC | 0.557(0.351–0.885) | 0.014 |
| TCGA-CHOL | 0.918(0.364–2.319) | 0.856 |
| TCGA-COAD | 1.403(0.94–2.093) | 0.109 |
| TCGA-ESCA | 0.744(0.453–1.22) | 0.248 |
| TCGA-HNSC | 0.995(0.762–1.298) | 0.97 |
| TCGA-KICH | 0.86(0.233–3.181) | 0.822 |
| TCGA-KIRC | 1.567(1.157–2.121) | 0.003 |
| TCGA-GBM | NA | NA |
| TCGA-KIRP | 0.815(0.451–1.473) | 0.5 |
| TCGA-LIHC | 1.467(0.845–2.548) | 0.24 |
| TCGA-LUAD | 0.738(0.552–0.988) | 0.04 |
| TCGA-LUSC | 0.79(0.603–1.035) | 0.085 |
| TCGA-DLBC | 4.429(0.509–38.56) | 0.059 |
| TCGA-MESO | 0.567(0.352–0.913) | 0.013 |
| TCGA-OV | 0.921(0.711–1.193) | 0.53 |
| TCGA-PAAD | 0.89(0.591–1.339) | 0.574 |
| TCGA-PCPG | 2.648(0.526–13.329) | 0.231 |
| TCGA-PRAD | 0.541(0.155–1.883) | 0.362 |
| TCGA-READ | 1.541(0.711–3.337) | 0.29 |
| TCGA-SARC | 1.664(1.03–2.69) | 0.042 |
| TCGA-SKCM | 0.642(0.31–1.329) | 0.233 |
| TCGA-STAD | 1.82(1.195–2.771) | 0.022 |
| TCGA-TGCT | 2.269(0.314–16.419) | 0.455 |
| TCGA-THYM | 7.349(1.494–36.153) | 0.001 |
| TCGA-THCA | 3.954(0.929–16.837) | 0.004 |
| TCGA-UCS | 2.393(1.012–5.656) | 0.03 |
| TCGA-UCEC | 2.142(1.145–4.004) | 0.002 |
| TCGA-UVM | 1.461(0.645–3.311) | 0.365 |
| TCGA-LGG | 0.662(0.465–0.941) | 0.019 |
The data were subjected to the Kaplan-Meier method and log-rank test.
HR, hazard ratio; CI, confidence interval; OS, overall survival; NA, not available.
Bold indicate statistically significant values (P < 0.05).
ACC, adrenocortical cancer; BLCA, bladder cancer; BRCA, breast cancer; CESC, cervical cancer; CHOL, bile duct cancer; COAD, colon cancer; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, glioma, LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian cancer; PAAD, pancreatic cancer; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate cancer; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, melanoma; STAD, gastric cancer; TGCT, testicular tumors; THCA, thyroid cancer; THYM, thymoma; UCEC, endometrioid cancer; UCS, uterine carcinosarcoma; UVM, uveal melanoma.